Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Harmit Singh

Psychiatry Council Bluffs, IA Medical Doctor

NPI 1891927430 CMS profile 312544

801 Harmony St, Suite 302,, Council Bluffs, IA 51503

Open in the dashboard

General payments

$4,031

235 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Harmit Singh of Council Bluffs, IA is reported in the CMS Open Payments database as having received $4,031 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $1,367 67
2020 General $1,475 83
2019 General $1,190 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harmit Singh
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Harmit Singh were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Harmit Singh Psychiatry median Middle half National median
2019 $1,190 $184 $59–$605 $163
2020 $1,475 $119 $36–$372 $114
2021 $1,367 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Sunovion Pharmaceuticals Inc. $1,430 73 payments
  2. Alkermes, Inc. $716 48 payments
  3. Janssen Pharmaceuticals, Inc $577 29 payments
  4. Otsuka America Pharmaceutical, Inc. $470 33 payments
  5. ITI, Inc. $256 15 payments
  6. Allergan Inc. $238 15 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $113 7 payments
  8. Shire North American Group Inc $60 4 payments
  9. Vertical Pharmaceuticals, LLC $52 3 payments
  10. Vanda Pharmaceuticals Inc. $40 3 payments
  11. Other $79 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $3,981 233 payments
  2. Education $51 2 payments
Products named General payments · program years 2019–2021
  1. LATUDA $1,335 70 payments
  2. ARISTADA INITIO $716 48 payments
  3. ARISTADA Cns $716 48 payments
  4. ARISTADA Cns $716 48 payments
  5. ARISTADA Cns $716 48 payments
  6. ARISTADA Cns $716 48 payments
  7. INVEGA SUSTENNA $562 28 payments
  8. INVEGA TRINZA $408 23 payments
  9. ABILIFY MAINTENA $375 26 payments
  10. SPRAVATO $362 22 payments
  11. Other $1,075 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

440

Median for Psychiatry: 574

Drug cost

$50,220

Median for Psychiatry: $27,624

Branded share of claims

5.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 12 $38,329
Aripiprazole Generic 26 $2,568
Olanzapine Generic 18 $1,642
Fluphenazine Hcl Generic 11 $1,333
Trazodone Hcl Generic 82 $1,061
Duloxetine Hcl Generic 13 $992
Risperidone Generic 28 $849
Haloperidol Generic 15 $529
Hydroxyzine Hcl Generic 44 $522
Gabapentin Generic 26 $408

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$34,523

Medicare's payments for the services billed

Medicare patients

65

Average age 51

Services billed

508

34 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
High blood pressure 63%
Arthritis 34%
Diabetes 29%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record